Longitudinal associations between psychedelic use and psychotic symptoms in the United States and the United Kingdom
Ludwig Honk, Cecilia U.D. Stenfors, Simon B. Goldberg, Peter S. Hendricks, Walter Osika, Haley Maria Dourron, Alexander V. Lebedev, Predrag Petrović, Otto Simonsson
Journal of Affective Disorders January 26, 2024 DOI: 10.1016/j.jad.2024.01.197 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Longitudinal study Peer reviewed |
|---|---|
| Sample size | 9,732 |
| Population | US and UK adult populations representative with regard to sex, age, and ethnicity |
| Intervention | Psychedelic use |
| Duration | Two-month study period |
| Citations | 41 |
| Key findings | Psychedelic use was not associated with a change in psychotic symptoms overall, but it was associated with an increase in symptoms among those with a personal or family history of bipolar disorder and a decrease among those with a personal history of psychotic disorders. |
Abstract
It has long been speculated that psychedelic use could provoke the onset of psychosis, but there is little evidence to support this conjecture. Using a longitudinal research design with samples representative of the US and UK adult populations with regard to sex, age, and ethnicity (n = 9732), we investigated associations between psychedelic use and change in the number of psychotic symptoms during the two-month study period. In covariate-adjusted regression models, psychedelic use during the study period was not associated with a change in the number of psychotic symptoms unless it interacted with a personal or family history of bipolar disorder, in which case the number of symptoms increased, or with a personal (but not family) history of psychotic disorders, in which case the number of symptoms decreased. Taken together, these findings indicate that psychedelic use may affect psychotic symptoms in individuals with a personal or family history of certain disorders characterized by psychotic symptomatology.
Citations in the library
Cited by 37
- Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies. Molecular Psychiatry March 1, 2025
- Emergency Department Visits Involving Hallucinogen Use and Risk of Schizophrenia Spectrum Disorder. JAMA Psychiatry February 1, 2025
- On Minimizing Risk and Harm in the Use of Psychedelics. Psychiatric Research and Clinical Practice February 11, 2025
- Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms. Psychological Medicine March 31, 2025
- Psychedelic iatrogenic structural dissociation: an exploratory hypothesis on dissociative risks in psychedelic use. Frontiers in Psychology March 4, 2025
and 32 more in the library
Cites 43
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
and 38 more in the library